Autolus Therapeutics plc Stock-Based Compensation
Autolus Therapeutics plc (AUTL) reported Stock-Based Compensation of $4.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-11
- Autolus Therapeutics plc share-based payment arrangement, expense for the quarter ending 2026-06-30 was $4.59M, a 7.03% increase year-over-year.
- Autolus Therapeutics plc share-based payment arrangement, expense for the quarter ending 2026-03-31 was $3.56M, a 24.35% increase year-over-year.
- Autolus Therapeutics plc share-based payment arrangement, expense for the quarter ending 2025-12-31 was $3.44M, a 44.76% decline year-over-year.
- Autolus Therapeutics plc share-based payment arrangement, expense for the quarter ending 2025-09-30 was $3.83M, a 4.60% decline year-over-year.
- Autolus Therapeutics plc share-based payment arrangement, expense for fiscal 2025 was $14.44M, a 6.68% decline from fiscal 2024.
- Autolus Therapeutics plc share-based payment arrangement, expense for fiscal 2024 was $15.47M, a 38.09% increase from fiscal 2023.
- Autolus Therapeutics plc share-based payment arrangement, expense for fiscal 2023 was $11.20M, a 6.74% decline from fiscal 2022.
- Autolus Therapeutics plc share-based payment arrangement, expense for fiscal 2022 was $12.01M, a 20.90% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $4.59M 10-Q · filed 2026-08-11 | $8.16M 10-Q · filed 2026-08-11 | $11.60M derived: sum of 3 quarters · filed 2026-08-11 | $15.44M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $3.56M 10-Q · filed 2026-05-14 | $7.01M derived: sum of 2 quarters · filed 2026-05-14 | $10.84M derived: sum of 3 quarters · filed 2026-05-14 | $15.14M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $7.28M derived: sum of 2 quarters · filed 2026-03-27 | $11.57M derived: sum of 3 quarters · filed 2026-08-11 | $14.44M 10-K · filed 2026-03-27 | |
| 2025-09-30 | $3.83M 10-Q · filed 2025-11-12 | $8.13M derived: sum of 2 quarters · filed 2026-08-11 | $10.99M 10-Q · filed 2025-11-12 | $17.23M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $4.29M 10-Q · filed 2026-08-11 | $7.16M 10-Q · filed 2026-08-11 | $13.39M derived: sum of 3 quarters · filed 2026-08-11 | $17.41M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $2.87M 10-Q · filed 2026-05-14 | $9.10M derived: sum of 2 quarters · filed 2026-05-14 | $13.12M derived: sum of 3 quarters · filed 2026-05-14 | $16.05M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $6.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $10.25M derived: sum of 2 quarters · filed 2026-03-27 | $13.19M derived: sum of 3 quarters · filed 2026-03-27 | $15.47M 10-K · filed 2026-03-27 | |
| 2024-09-30 | $4.02M 10-Q · filed 2025-11-12 | $6.96M derived: sum of 2 quarters · filed 2025-11-12 | $9.24M 10-Q · filed 2025-11-12 | $12.49M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $2.94M 10-Q · filed 2025-08-12 | $5.22M 10-Q · filed 2025-08-12 | $8.47M derived: sum of 3 quarters · filed 2025-08-12 | $11.34M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $2.28M 10-Q · filed 2025-05-08 | $5.54M derived: sum of 2 quarters · filed 2025-05-08 | $8.40M derived: sum of 3 quarters · filed 2025-05-08 | $11.07M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $3.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $6.12M derived: sum of 2 quarters · filed 2025-03-20 | $8.79M derived: sum of 3 quarters · filed 2025-03-20 | $11.20M 10-K · filed 2025-03-20 | $11.25M 10-K · filed 2024-03-21 |
| 2023-09-30 | $2.86M 10-Q · filed 2024-11-12 | $5.53M derived: sum of 2 quarters · filed 2024-11-12 | $7.95M 10-Q · filed 2024-11-12 | $11.36M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $2.67M 10-Q · filed 2024-08-08 | $5.08M 10-Q · filed 2024-08-08 | $8.50M derived: sum of 3 quarters · filed 2024-08-08 | $11.84M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $2.42M 10-Q · filed 2024-05-17 | $5.83M derived: sum of 2 quarters · filed 2024-05-17 | $9.17M derived: sum of 3 quarters · filed 2024-05-17 | ||
| 2022-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $6.75M derived: sum of 2 quarters · filed 2024-03-21 | $12.01M 10-K · filed 2024-03-21 | ||
| 2022-09-30 | $3.34M 10-Q · filed 2023-11-09 | $8.60M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $9.94M 10-K · filed 2024-03-21 | ||||
| 2021-03-31 | -$670.00K 6-K · filed 2021-05-06 | $3.56M derived: sum of 2 quarters · filed 2023-03-07 | $7.81M derived: sum of 3 quarters · filed 2023-03-07 | $13.12M derived: sum of 4 quarters · filed 2023-03-07 | |
| 2020-12-31 | $4.24M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-07 | $8.48M derived: sum of 2 quarters · filed 2023-03-07 | $13.79M derived: sum of 3 quarters · filed 2023-03-07 | $20.02M 20-F · filed 2023-03-07 | |
| 2020-09-30 | $4.25M 6-K · filed 2020-11-05 | $9.55M derived: sum of 2 quarters · filed 2020-11-05 | $15.79M 6-K · filed 2020-11-05 | $22.23M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-06-30 | $5.30M 6-K · filed 2020-08-06 | $11.54M 6-K · filed 2020-08-06 | $17.99M derived: sum of 3 quarters · filed 2022-03-10 | $25.70M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2020-03-31 | $6.24M 6-K · filed 2021-05-06 | $12.68M derived: sum of 2 quarters · filed 2022-03-10 | $20.39M derived: sum of 3 quarters · filed 2022-03-10 | $29.26M derived: sum of 4 quarters · filed 2022-03-10 | |
| 2019-12-31 | $6.45M derived: 20-F 12 month − 6-K 9 month · filed 2022-03-10 | $14.15M derived: sum of 2 quarters · filed 2022-03-10 | $23.02M derived: sum of 3 quarters · filed 2022-03-10 | $30.39M 20-F · filed 2022-03-10 | |
| 2019-09-30 | $7.71M 6-K · filed 2020-11-05 | $16.57M derived: sum of 2 quarters · filed 2020-11-05 | $23.94M 6-K · filed 2020-11-05 | $27.33M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-06-30 | $8.87M 6-K · filed 2020-08-06 | $16.23M 6-K · filed 2020-08-06 | $19.62M derived: sum of 3 quarters · filed 2021-03-04 | $22.68M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-03-31 | $7.37M 6-K · filed 2020-05-07 | $10.76M derived: sum of 2 quarters · filed 2021-03-04 | $13.81M derived: sum of 3 quarters · filed 2021-03-04 | $16.19M derived: sum of 4 quarters · filed 2021-03-04 | |
| 2018-12-31 | $3.39M 20-F · filed 2021-03-04 | $6.45M derived: sum of 2 quarters · filed 2021-03-04 | $8.82M derived: sum of 3 quarters · filed 2021-03-04 | ||
| 2018-09-30 | $3.05M derived: 20-F 9 month − 6-K 6 month · filed 2021-03-04 | $5.43M derived: sum of 2 quarters · filed 2021-03-04 | $6.76M 20-F · filed 2021-03-04 | $6.76M 20-F · filed 2020-03-03 | |
| 2018-06-30 | $2.38M 6-K · filed 2019-08-08 | $3.71M 6-K · filed 2019-08-08 | |||
| 2017-09-30 | $3.15M 20-F · filed 2020-03-03 | ||||
| 2016-09-30 | $2.26M 20-F · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |